A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension

Journal of Human Hypertension

Volumn 22, Issue 4, 2008, Pages 266-274

  Neutel, J M ^a   Franklin, S S ^b   Lapuerta, P ^c   Bhaumik, A ^c   Ptaszynska, A ^c  

^a Orange County Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN; PLACEBO;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 41049093646     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002293     Document Type: Article

References (28)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-223.
2. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: A systematic review. J Hypertens 2004; 22: 11-19.
3. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: Trends in prevalence, incidence, and control. Annu Rev Public Health 2006; 27: 465-490.
4. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006; 8: 93-98.
5. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1963.
6. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21: 973-985.
7. Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J 1991; 121 664-669.
8. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-457.
9. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M, ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: Results of the ForLife study. J Hypertens 2005; 23 1575-1581.
10. Mancia G, Parati G, Borgbi C, Ghironzi G, Andriani E, Marinelli L, et al., SMOOTH investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: The SMOOTH study. J Hypertens 2006; 24: 837-843.
11. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345-351.
12. Hypertension Call to Action 2006. Available at http://www.eshonline.org/ education/congresses/2006/esh/call_to_action.aspaccessed on 5th February 2007.
13. Franklin SS, Jacobs MJ, Wong ND, L'Ialien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: Analysis based on National Health and Nutrition Examination Survey (NHANES.) III. Hypertension 2001; 37(3): 869-874.
14. Skolink NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000; 61: 3049-3056.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC-7 Report. JAMA 2003; 289: 2560-2572.
16. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28: 1462-1536.
17. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003; 9: 324-332.
18. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7: 578-586.
19. Pool JL, Guthrie RM, Littlejohn III TW, Raskin P, Shephard AM, Weber MA et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-470.
20. Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-h ambulatory blood pressure monitoring. Clin Exp Hypertens 1999; 21: 1373-1396.
21. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797-805.
22. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: Recommendations of the European Society of Hypertension. BMJ 2001; 322: 531-536.
23. Laska EM, Meisner MJ. Testing whether an identified treatment is best. Biometrics 1989; 45: 1139-1151.
24. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
25. Ridker PM, Danielson E, Rifai N, Glynn RJ, Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension 2006; 48: 73-79.
26. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens 2006; 8: 850-857.
27. Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18: 1482-1488.
28. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-142.